Clinical trial NCT03898336: Eat2beNICE Vitamins and Nutrients as Supplementation for Impulsivity, Irritability, and Compulsivity
Official title: Eat2beNICE Vitamins and Nutrients as Supplementation for Impulsivity, Irritability, and Compulsivity
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Impulsive Behavior
Lead sponsor: Radboud University Medical Center
Sponsor class: OTHER
Collaborators: name: Central Institute of Mental Health, Mannheim
name: University Medical Center Groningen
First posted: 2019-04-01
Enrollment: 210
Sex: ALL
Minimum age (years): 11
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: double-blind placebo controlled following open label phase
Primary purpose: TREATMENT

Brief summary: Impulsivity, irritability and compulsivity are cross-disorder symptom domains, which affect a significant proportion of adolescents.

Predominately as part of attention deficit hyperactivity disorder (ADHD) but also as symptom domains without a diagnosis of ADHD, impulsivity and irritability cause serious burden. Furthermore, treatment options and their effects are limited.

Previous studies with different study designs assessing micronutrients for the treatment of impulsivity / ADHD in children and adults have reported positive benefits as well as a very good tolerability. However, more research is required; in particular controlled studies with adolescents, cross-disorder approaches and studies investigating long-term effects are missing.

The focus of this study is to investigate the effect of micronutrients on impulsivity, irritability and compulsivity in children and adolescents between 11 and 18 years of age with a high level of impulsivity and irritability with or without a diagnosis of attention deficit hyperactivity disorder (ADHD).

The investigators intend to include 210 children and adolescents (n=110 in Germany) with a high level of impulsivity and irritability.

The study is divided in two phases. An initial 10-week double blind, placebo-controlled treatment phase with broad-spectrum micronutrients is followed by a 10-week open-label treatment phase. The study assessments will be performed during five study visits and a follow-up visit.


Eligibility criteria: Inclusion Criteria:

* Male or female, aged 11;0 - 17; 6 years at initial inclusion
* Subjects with a high level of impulsivity/ irritability based on a CGI-S-score ≥ 4 and a parent-rated Affective Reactivity Index (ARI) score ≥ 5 indicating a high level of multi-dimensional irritability
* Subjects with or without a research diagnosis of attention deficit hyperactivity disorder (ADHD). ADHD has to be confirmed by structured diagnostic interview (ADHD section of Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS))
* Deemed reliable and compliant with the protocol (including the ingestion of as many capsules as prescribed by the investigator)
* Ability to comprehend and speak the native language of the country in which the assessments take place
* Signed informed consent by parents or legal representative
* Signed informed assent by child or adolescent (indicating that the subject is aware of the investigational nature and the core aspects of the study and the study is run in accordance with the ICH GCP guideline E6 (R2) (2016))

Exclusion Criteria:

* Subject is being treated with a medication that might, in the opinion of the investigator, pose a safety risk for the subject when participating in this study
* Intellectual disability (based on available IQ or the clinical opinion of the investigator, taking into account relevant psychosocial information, e.g. educational level)
* Any known abnormality of mineral metabolism (e.g., Wilson's disease, haemochromatosis)
* History of or present clinically relevant somatic or psychiatric acute or chronic disorder that, in the opinion of the investigator, might confound the results of tolerability/safety assessment, or prohibit the patients from completing the study, or would not be in the best interest of the patient.
* Subject has taken any kind of food supplement containing vitamins, minerals and/or trace elements within 30 days prior to entering the study
* Subject has unstable treatment conditions (current changes in medication and/or psychotherapy) that might in the opinion of the investigator confound the results of the study with respect to impulsivity/irritability.
* Subject has a documented allergy, hypersensitivity, or intolerance to any of the ingredients of the investigational product
* Subject has taken another investigational product or taken part in a clinical study within 30 days prior to entering the study

Primary outcomes:
measure: response rate at end of placebo-controlled phase defined as CGI-I score with focus on impulsivity of 1 or 2 [=very much improved or much improved] plus reduction in Affective Reactivity Index (ARI) total score of at least 30% compared to baseline
timeFrame: 10 weeks (end of placebo-controlled phase)
Secondary outcomes:
measure: Change in Clinician rating of compulsivity
timeFrame: every 10 weeks over the whole study period of 20 weeks (10 weeks placebo-controlled phase followed by 10 weeks open label)
measure: Change in the rating of irritability
timeFrame: every 10 weeks over the whole study period of 20 weeks (10 weeks placebo-controlled phase followed by 10 weeks open label)
measure: Change in sleep problems
timeFrame: every 10 weeks over the whole study period of 20 weeks (10 weeks placebo-controlled phase followed by 10 weeks open label)
measure: change in motor activity (optional)
timeFrame: at baseline and after 10 weeks of study participation
measure: Change in ADHD symptom severity total score
timeFrame: every 10 weeks over the whole study period of 20 weeks (10 weeks placebo-controlled phase followed by 10 weeks open label)
measure: change in rating of aggression
timeFrame: every 5 weeks over the whole study period of 20 weeks (10 weeks placebo-controlled phase followed by 10 weeks open label)
measure: Rates of adverse events of the treatment groups in comparison to placebo group
timeFrame: every 5 weeks over the whole study period of 20 weeks (10 weeks placebo-controlled phase followed by 10 weeks open label)
measure: change in treatment adherence
timeFrame: every 10 weeks over the whole study period of 20 weeks (10 weeks placebo-controlled phase followed by 10 weeks open label)
Other outcomes:
Locations:
city: Mannheim
country: Germany
facility: Central Institute of Mental Health
Study officials:
affiliation: Central Institute of Mental Health, Mannheim
name: Alexander Haege, Dr.
role: PRINCIPAL_INVESTIGATOR
References: